Boca Raton, Florida, Sept. 13, 2024

INmune Bio Inc. Announces Registered Direct Offering

INmune Bio Inc. (Nasdaq: INMB) recently announced that it has entered into securities purchase agreements for the purchase and sale of 2,341,260 shares of its common stock and warrants to purchase up to the same number of shares. The offering is aimed at raising funds for the development of treatments that harness a patient’s innate immune system to fight disease.

INmune Bio is a clinical-stage inflammation and immunology company that is dedicated to revolutionizing the way we approach disease treatment. By focusing on the innate immune system, the company is tapping into the body’s natural defenses to combat illnesses in a more effective and sustainable way.

The securities purchase agreements include participation from both institutional investors and Insiders, which consist of certain directors, officers, and employees of the company. The purchase price per share and accompanying warrant varies for institutional investors and Insiders, with warrants becoming exercisable after six months from the date of issuance.

This registered direct offering signifies a major milestone for INmune Bio and reinforces the company’s commitment to advancing innovative treatments that have the potential to transform the healthcare landscape. With the funds raised, the company can further its research and development efforts, bringing us one step closer to a future where diseases can be effectively targeted and treated.

How This Will Affect Me

As a potential investor or individual interested in advancements in healthcare, this news could have a direct impact on you. INmune Bio’s innovative approach to leveraging the innate immune system for disease treatment could lead to groundbreaking developments in the field of medicine. By supporting the company through this offering, you are contributing to the progress of cutting-edge treatments that have the potential to improve health outcomes globally.

How This Will Affect the World

The implications of INmune Bio’s registered direct offering extend far beyond individual investors or the company itself. The success of this fundraising initiative could pave the way for significant advancements in healthcare on a global scale. By unlocking the potential of the innate immune system, INmune Bio is forging a path towards more effective, personalized treatments that could benefit populations worldwide and create a lasting impact on the way we approach disease management.

Conclusion

The announcement of INmune Bio’s registered direct offering marks a pivotal moment in the company’s journey to revolutionize disease treatment through harnessing the innate immune system. With the support of institutional investors, Insiders, and individuals like yourself, the company is poised to make significant strides in developing innovative therapies that have the potential to transform healthcare outcomes. As we look towards the future, the impact of this offering on both individual investors and the global community underscores the importance of investing in cutting-edge research and development efforts that have the power to change lives.